BMY - Bristol-Myers posts another sales decline in Q3 amid Revlimid overhang
2023-10-26 07:45:00 ET
More on Bristol-Myers
- Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
- Bristol-Myers Squibb: Time To Get Greedy
- Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
- Bristol-Myers Squibb Company Non-GAAP EPS of $2.00 beats by $0.23, revenue of $10.97B in-line
- Bristol Myers expected to report lower Q3 earnings amid generic competition
For further details see:
Bristol-Myers posts another sales decline in Q3 amid Revlimid overhang